TKB 662

Drug Profile

TKB 662

Alternative Names: TKB-662

Latest Information Update: 27 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isotechnika
  • Class
  • Mechanism of Action Lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 27 Sep 2013 Discontinued - Preclinical for Transplant rejection in Canada (unspecified route)
  • 31 Dec 2006 No development reported - Preclinical for Transplant rejection in Canada (unspecified route)
  • 05 Nov 2004 TKB 662 is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top